IBDEI0C3 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5737,2)
 ;;=^88213
 ;;^UTILITY(U,$J,358.3,5738,0)
 ;;=302.72^^49^514^2
 ;;^UTILITY(U,$J,358.3,5738,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5738,1,4,0)
 ;;=4^MALE ERECTILE DYSFUNCTION
 ;;^UTILITY(U,$J,358.3,5738,1,5,0)
 ;;=5^302.72
 ;;^UTILITY(U,$J,358.3,5738,2)
 ;;=^73439
 ;;^UTILITY(U,$J,358.3,5739,0)
 ;;=194.0^^49^515^2
 ;;^UTILITY(U,$J,358.3,5739,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5739,1,4,0)
 ;;=4^ADRENAL TUMOR,MALIGNANT
 ;;^UTILITY(U,$J,358.3,5739,1,5,0)
 ;;=5^194.0
 ;;^UTILITY(U,$J,358.3,5739,2)
 ;;=^267298
 ;;^UTILITY(U,$J,358.3,5740,0)
 ;;=255.10^^49^515^4
 ;;^UTILITY(U,$J,358.3,5740,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5740,1,4,0)
 ;;=4^ALDOSTERONISM,PRIMARY
 ;;^UTILITY(U,$J,358.3,5740,1,5,0)
 ;;=5^255.10
 ;;^UTILITY(U,$J,358.3,5740,2)
 ;;=^330019
 ;;^UTILITY(U,$J,358.3,5741,0)
 ;;=255.14^^49^515^3
 ;;^UTILITY(U,$J,358.3,5741,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5741,1,4,0)
 ;;=4^ALDOSTERNISM,SECONDARY
 ;;^UTILITY(U,$J,358.3,5741,1,5,0)
 ;;=5^255.14
 ;;^UTILITY(U,$J,358.3,5741,2)
 ;;=^329907
 ;;^UTILITY(U,$J,358.3,5742,0)
 ;;=255.10^^49^515^5
 ;;^UTILITY(U,$J,358.3,5742,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5742,1,4,0)
 ;;=4^HYPERALDOSTERONISM
 ;;^UTILITY(U,$J,358.3,5742,1,5,0)
 ;;=5^255.10
 ;;^UTILITY(U,$J,358.3,5742,2)
 ;;=^330019
 ;;^UTILITY(U,$J,358.3,5743,0)
 ;;=227.0^^49^515^6
 ;;^UTILITY(U,$J,358.3,5743,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5743,1,4,0)
 ;;=4^PHEOCHROMOCYTOMA,BENIGN
 ;;^UTILITY(U,$J,358.3,5743,1,5,0)
 ;;=5^227.0
 ;;^UTILITY(U,$J,358.3,5743,2)
 ;;=^267688
 ;;^UTILITY(U,$J,358.3,5744,0)
 ;;=733.00^^49^516^8
 ;;^UTILITY(U,$J,358.3,5744,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5744,1,4,0)
 ;;=4^OSTEOPOROSIS NOS
 ;;^UTILITY(U,$J,358.3,5744,1,5,0)
 ;;=5^733.00
 ;;^UTILITY(U,$J,358.3,5744,2)
 ;;=^87159
 ;;^UTILITY(U,$J,358.3,5745,0)
 ;;=733.01^^49^516^12
 ;;^UTILITY(U,$J,358.3,5745,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5745,1,4,0)
 ;;=4^OSTEOPOROSIS,SENILE
 ;;^UTILITY(U,$J,358.3,5745,1,5,0)
 ;;=5^733.01
 ;;^UTILITY(U,$J,358.3,5745,2)
 ;;=^87188
 ;;^UTILITY(U,$J,358.3,5746,0)
 ;;=733.02^^49^516^11
 ;;^UTILITY(U,$J,358.3,5746,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5746,1,4,0)
 ;;=4^OSTEOPOROSIS,IDIOPATHIC
 ;;^UTILITY(U,$J,358.3,5746,1,5,0)
 ;;=5^733.02
 ;;^UTILITY(U,$J,358.3,5746,2)
 ;;=^272692
 ;;^UTILITY(U,$J,358.3,5747,0)
 ;;=733.03^^49^516^9
 ;;^UTILITY(U,$J,358.3,5747,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5747,1,4,0)
 ;;=4^OSTEOPOROSIS,DISUSE
 ;;^UTILITY(U,$J,358.3,5747,1,5,0)
 ;;=5^733.03
 ;;^UTILITY(U,$J,358.3,5747,2)
 ;;=^265526
 ;;^UTILITY(U,$J,358.3,5748,0)
 ;;=733.09^^49^516^10
 ;;^UTILITY(U,$J,358.3,5748,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5748,1,4,0)
 ;;=4^OSTEOPOROSIS,DRUG-INDUCED
 ;;^UTILITY(U,$J,358.3,5748,1,5,0)
 ;;=5^733.09
 ;;^UTILITY(U,$J,358.3,5748,2)
 ;;=^87762
 ;;^UTILITY(U,$J,358.3,5749,0)
 ;;=268.2^^49^516^6
 ;;^UTILITY(U,$J,358.3,5749,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5749,1,4,0)
 ;;=4^OSTEOMALACIA NOS
 ;;^UTILITY(U,$J,358.3,5749,1,5,0)
 ;;=5^268.2
 ;;^UTILITY(U,$J,358.3,5749,2)
 ;;=^87103
 ;;^UTILITY(U,$J,358.3,5750,0)
 ;;=756.52^^49^516^7
 ;;^UTILITY(U,$J,358.3,5750,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5750,1,4,0)
 ;;=4^OSTEOPETROSIS
 ;;^UTILITY(U,$J,358.3,5750,1,5,0)
 ;;=5^756.52
 ;;^UTILITY(U,$J,358.3,5750,2)
 ;;=^87143
 ;;^UTILITY(U,$J,358.3,5751,0)
 ;;=579.9^^49^516^1
 ;;^UTILITY(U,$J,358.3,5751,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5751,1,4,0)
 ;;=4^MALABSORPTION SYNDROME
 ;;^UTILITY(U,$J,358.3,5751,1,5,0)
 ;;=5^579.9
